Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
TRIFLURIDINE/TIPIRACIL (FTD/TPI) IN PATIENTS (PTS) AGED ≥ 65 YEARS WITH METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER (MGC/MGEJC): SUBGROUP ANALYSIS FROM TAGS
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Gastrointestinal (Noncolorectal) Cancer / Esophageal or Gastric Cancer Type Poster Session (Monday,...
Maintenance Therapy with PARP Inhibitor Olaparib Delays Progression of BRCA–Related Pancreatic Cancer
19 srpna, 2020 12:54 pmJune 2, 2019 “We are eagerly awaiting longer-term data to understand the full impact of the results from this...
Front-Line Pembrolizumab Is Promising Alternative to Chemotherapy for Advanced Gastroesophageal Junction and Gastric Cancers
19 srpna, 2020 12:54 pmJune 1, 2019 “Chemotherapy has been our only option for many years. These results introduce a potential alternative in...
Najvýznamnejšie klinické správy z konferencie ASCO© 2019 v problematike nádorov gastrointestinálneho traktu
19 srpna, 2020 12:54 pmPočas prvého júnového týždňa tohto roku sa konal v Chicagu tradičný výročný kongres Americkej onkologickej spoločnosti (ASCO®). Ako obvykle v rámci prednášok...
A RANDOMIZED PHASE 3 TRIAL OF PACLITAXEL (P) PLUS CARBOPLATIN (C) VERSUS PACLITAXEL PLUS IFOSFAMIDE (I) IN CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE I-IV, PERSISTENT OR RECURRENT CARCINOSARCOMA OF THE UTERUS OR OVARY: AN NRG ONCOLOGY TRIAL
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Gynecologic Cancer / Uterine Cancer Type Oral Abstract Session (Monday, June 3,...
FIRST RESULTS FROM TITAN: A PHASE III DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) VERSUS PLACEBO (PBO) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) RECEIVING ANDROGEN DEPRIVATION THERAPY (ADT)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Genitourinary (Prostate) Cancer Type Oral Abstract Session (Friday, May 31, 2019) ...
CALGB 90601 (ALLIANCE): RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL COMPARING GEMCITABINE AND CISPLATIN WITH BEVACIZUMAB OR PLACEBO IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Genitourinary (Nonprostate) Cancer Type Oral Abstract Session (Monday, June 3, 2019) ...
PEMBROLIZUMAB (PEMBRO) PLUS AXITINIB (AXI) VERSUS SUNITINIB AS FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC): OUTCOMES IN THE COMBINED IMDC INTERMEDIATE/POOR RISK AND SARCOMATOID SUBGROUPS OF THE PHASE 3 KEYNOTE-426 STUDY
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Genitourinary (Nonprostate) Cancer Type Oral Abstract Session (Monday, June 3, 2019) ...
Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients with Advanced Urothelial Cancer
19 srpna, 2020 12:54 pmJune 3, 2019 “If advanced urothelial cancer progresses following treatment with platinum-based chemotherapy and immunotherapy with checkpoint inhibitors there...
ASCO® 2019 – sekce genitourinárních karcinomů
19 srpna, 2020 12:54 pmAbstract ID: LBA2 Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide...